Country: Canada
Language: English
Source: Health Canada
TAMOXIFEN (TAMOXIFEN CITRATE)
PFIZER CANADA ULC
L02BA01
TAMOXIFEN
10MG
TABLET
TAMOXIFEN (TAMOXIFEN CITRATE) 10MG
ORAL
60, 250
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0131293001; AHFS:
CANCELLED POST MARKET
2007-10-02
PRODUCT MONOGRAPH TAMONE ® Tamoxifen Citrate Tablets USP 10 mg and 20 mg ANTINEOPLASTIC AGENT Pharmacia Canada Inc. DATE OF PREPARATION: Mississauga, Ontario December 17, 2001 DATE OF REVISION: CONTROL # 083918 September 10, 2003 ©Pharmacia Canada Inc. 2 PRODUCT MONOGRAPH NAME OF DRUG TAMONE ® Tamoxifen Citrate Tablets USP 10 mg and 20 mg THERAPEUTIC CLASSIFICATION Antineoplastic (non-steroidal antiestrogen) TAMOXIFEN THERAPY WAS ASSOCIATED WITH SERIOUS AND LIFE-THREATENING EVENTS INCLUDING UTERINE MALIGNANCIES, STROKE, PULMONARY EMBOLISM, AND DEEP VEIN THROMBOSIS IN THE NSABP P-1 BREAST CANCER PREVENTION TRIAL. THE USE OF TAMOXIFEN FOR BREAST CANCER PREVENTION IS NOT AN APPROVED INDICATION IN CANADA. THE FOLLOWING RISKS ASSOCIATED WITH TAMOXIFEN THERAPY HAVE BEEN ESTIMATED FROM THE NSABP P-1 BREAST CANCER PREVENTION TRIAL. THE RELATIVE RISK OF TAMONE COMPARED TO PLACEBO WAS 3.1 FOR ENDOMETRIAL CANCER, 4.0 FOR UTERINE SARCOMAS, 1.6 FOR STROKE, 3.0 FOR PULMONARY EMBOLISM, AND 1.6 FOR DEEP VEIN THROMBOSIS. THESE EVENTS WERE FATAL IN SOME PATIENTS. HEALTH CARE PROVIDERS SHOULD BE AWARE OF THE POSSIBLE RISKS ASSOCIATED WITH TAMOXIFEN THERAPY AND SHOULD DISCUSS THEM WITH THEIR PATIENTS. THE BENEFITS OF TAMOXIFEN THERAPY OUTWEIGH THE RISKS IN THE MAJORITY OF WOMEN BEING TREATED ACCORDING TO THE APPROVED CANADIAN INDICATION FOR THE TREATMENT OF BREAST CANCER. ACTIONS AND CLINICAL PHARMACOLOGY TAMONE (tamoxifen citrate) is a non-steroidal agent which has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects are related to its ability to compete with estrogen for binding sites in target tissues such as breast and uterus. Tamoxifen inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA- induced tumours. In this rat model tamoxifen appears to exert its antitumour effects by binding to estrogen receptors. 3 In cytosols derived from human endometrium and human breast and uterine adenocarcinomas Read the complete document